Drug Profile

Drug: Canagliflozin
Condition: Diabetes Mellitus Type 2
Brand Names: Invokana, Vokanamet
Keywords: SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA
BNF Codes: Please select a BNF chapter code to go to the formulary.
060102 - Antidiabetic Drugs

Committee Recommendations

Date Committee Name Narrative Traffic Light Status Traffic Light Status
07 February 2018 Prescribing Clinical Network Not a preferred treatment option.

See guidelines below and associated documentation for further information

PCN noted that Canagliflozin is a treatment option in NICE TA 315 & TA390
See Below

Documents

Type: Document (click to view) Review Date
Guidelines (Local) Diabetes Type 2 -Treatment Guidelines - February 2018 Diabetes Type 2 -Treatment Guidelines - February 2018 PDF February 2021
NICE TA NICE TA315 - Canagliflozin in combination therapy for treating Type 2 Diabetes - June 2014 NICE TA315 - Canagliflozin in combination therapy for treating Type 2 Diabetes - June 2014 PDF
NICE TA NICE TA390 - SGLT-2s for treating Type 2 diabetes - May 2016 NICE TA390 - SGLT-2s for treating Type 2 diabetes - May 2016 PDF
Miscellaneous SGLT2 inhibitors - Prescribing Initiation checklist - Aug 2015 SGLT2 inhibitors - Prescribing Initiation checklist - Aug 2015 PDF August 2017
Miscellaneous SGLT2 inhibitors - Prescribing Safety advice - Aug 2015 SGLT2 inhibitors - Prescribing Safety advice - Aug 2015 PDF August 2017
Information Hypoglycaemic agents -Preferred choices - February 2018 Hypoglycaemic agents -Preferred choices - February 2018 PDF February 2021
Information Blood glucose control - Treatment algorithm - February 2018 Blood glucose control - Treatment algorithm - February 2018 PDF February 2021
Information Antidiabetic treatments comparison- PrescQIPP resource - February 2018 Antidiabetic treatments comparison- PrescQIPP resource - February 2018 PDF February 2021

Supplementary documents (organisational specific)

No Supplementary Documents returned.